

PHYSICIANS' DESK REFERENCE®


PDR.net

FDA-approved Drug Alerts
Label Updates and CME

Adverse Drug Event Reporting
Patient Resource Guide







PHYSICIANS' DESK PEEPPINGE

CEO: Edward Fotsch, MD

President: Richard C. Altus

Chief Medical Officer: Steven Merahn, MD

Chief Technology Officer: David Cheng

Chief Financial Officer: Dawn Carfora

Senior Vice President, Publishing & Operations: Valerie E. Berger Vice President, Emerging Products: Debra Del Guidice Senior Vice President, Product Sales, Corporate Development & General Counsel: Andrew Gelman Senior Vice President, Sales: John Loucks Senior Vice President, Product Management: Lucian Taylor

Vice President, Business Development: Tom Dieker

Director of Sales: Eileen Bruno
Senior Business Manager: Karen Fass
Senior Account Executive: Marjorie Jaxel
Account Executives: Nick Clark, Carlos Cornejo, Michael Loechel,
Hitesh Mistry, Gary Naccarato
Director, Regulatory Solutions: Chris Thornton

Senior Director, Operations & Client Services: Stephanie Struble Director, Clinical Services: Sylvia Nashed, PharmD Director, Marketing: Kim Marich

Client Services Manager: Kathleen O'Brien

Manager, Clinical Services: Nermin Shenouda, PharmD

Senior Drug Information Specialist,

Database Management: Christine Sunwoo, PharmD

Senior Drug Information Specialist,

Product Development: Anila Patel, PharmD

Drug Information Specialists: Pauline Lee, PharmD;

Peter Leighton, PharmD; Kristine Mecca, PharmD

Clinical Editor: Julia Tonelli, MD

Managing Editor: J. Harris Fleming, Jr.

Manager, Art Department: Livio Udina

Associate Director, Manufacturing & Distribution: Thomas Westburgh
Senior Production Manager, PDR: Steven Maher
Senior Manager, Content Operations: Noel Deloughery
Senior Index Editor: Allison O'Hare
Index Editor: Julie L. Cross
Senior Production Coordinator: Yasmin Hernández
Production Coordinators: Eric Udina, Christopher Whalen
Associate Manager, Fulfillment: Gary Lew
Web Operations and Customer Service Manager: Lee Reynolds

Senior Director, Content Operations: Jeffrey D. Schaefer

Copyright © 2011 PDR Network, LLC. Published by PDR Network, LLC at Montvale, NJ 07645-1725. All rights reserved. None of the content of this publication may be reproduced, stored in a retrieval system, resold, redistributed, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording, or otherwise) without the prior written permission of the publisher. Physicians' besk Reference® and PDR® are registered trademarks of PDR Network, LLC. PDR® for Ophthalmic Medicines; PDR® to Nonprescription Drugs; PDR® Pharmacopoela; and PDR®3D are trademarks of PDR Network, LLC.

ISBN: 978-1-56363-800-8



Any known the form Coadminis 1000nazole

dence of consient isch

ipsychotic Neurolepti diate disco Jardive Dy (5.4).

_{bee}n assoc

cardiovas

changes in gain (5.5). Hypergiy tients for sia, polyu regularly , pyslipide

rved in . Weight G clinical m Hyperprola

, Leukopenia

reported wi low white b (CBC) moni therapy and

sign of a dec factors (5.7)

cardia or bri

early in tre known cardi antipsychotic Selzures: U zures or with

Potential for

tion when op Suicide: Th

n schizophr (5.12). See Full Pre

INGS and PR

Commonly obs lleast twice th

athisia, nausea. Io report SUS

1800-FDA-1088

LATUDA is no

with strong C

Dose adjustm

phibitors (e.g., LATUDA is no

with strong CY

—USE II

Gerlatric Use:

Pregnancy: U

Nursing Mothe

^{Redia}tric Use:

ablished (8.4).

Renal Impairm

¹⁰ 17 for PATIE

AL PRESCRIBIN

ARNING: INC TENTS WITH

INDICATION

DOSAGE A

2.1. Schi 2.2. Adm

ME

tic Impairi





Figure 3



• If your COPD symptoms worsen over time do not increase your dose of BROVANA, instead call your healthcare proto grada mini esinten ap e. Di grada mini esinten ap e.

وبماء بالوجو إرتيان باجرون

- · Increased blood pressure
- Fast or irregular heartbeat

in short & below for oft mour to

· serious allergic reactions including rash, hives, swelling of the face, mouth, and tongue, and breathing problems. Call your healthcare provider or get emergency medical care if you get any symptoms of a serious allergic reaction.

Common side effects of BROVANA include: echest or back pain to the pai

- nervousness the second resident to the second resident resi
- leg cramps
 high blood potassium
 shortness of breath
- shortness of breath was for orders and a been not work
- fever
- year yevene jakalar medidaa Increased white blood cells

 vomiting (A/OW)

 tiredness upon a both spice and a both with tadily

 leg swelling that the page that the tadily

 chest congestion or bronchitis

 AMAZORS upon your

 chest congestion or bronchitis

 chest cong • increased white blood cells

Tell your healthcare provider if you get any side effect that bothers you or that does not go away.




Figure 5 reliave your breathing

PARAVORS RICHARD which is the best from 1 into soon day included the world




Figure 6

These are not all the side effects with BROVANA. Ask your healthcare provider or pharmacist for more information. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store BROVANA?

 Store BROVANA in a refrigerator between 36° to 46°F (2° to 8°C) in the protective foil pouch. Protect from light and excessive heat. Do not open a sealed pouch until you are ready to use a dose of BROVANA. After opening the pouch, unused ready-to-use vials should be returned to, and stored in, the pouch. An opened ready-to-use vial should be used right away. BROVANA may be used directly from the refrigerator.

· BROVANA may also be stored at room temperature between 68°F to 77°F (20°C to 25°C) for up to 6 weeks (42 days). If stored at room temperature, discard BROVANA if it is not used after 6 weeks or if past the expiration date, whichever is sooner. Space is provided on the packaging to record room temperature storage times.

- Do not use BROVANA after the expiration date provided on the foil nouch and ready-to-use vial
- BROVANA should be colorless. Discard BROVANA if it is
- Keep BROVANA and all medicines out of the reach of children.

General Information about BROVANA

Medicines are sometimes prescribed for purposes not mentioned in a Medication Guide. Do not use BROVANA for a condition for which it was not prescribed. Do not give BROVANA to other people, even if they have the same con-

BROVANA to other people, even it may have the same condition. It may harm them.

This Medication Guide summarizes the most important information about BROVANA. If you would like more information, talk with your healthcare provider, You can asyour healthcare provider or pharmacist for information about BROVANA that was written for healthcare professionals.

- For customer service, call 1-888-394-7377.
- For customer service, call 1-888-394-1011.
 To report side effects, call 1-877-737-7326.
 For medical information, call 1-809-739-0565.
 Instructions for Using BROVANA (arformoterol tartrate) Inhalation Solution.

 BROVANA is used only in a standard jet nebulizer mechine and a standard standard service you know the compressor. Make sure you know the standard service y

connected to an air compressor. Make sure you know how to use your nebulizer machine before you use it to breathe in BROVANA or other medicines.

Do not mix BROVANA with other medicines in your nebus

Do not mix BROVANA with other liberalizer machine.

BROVANA comes sealed in a foil pouch. Do not open a sealed pouch until you are ready to use a dose of BROVANA After opening the pouch, unused ready-to-use vials should be returned to, and stored in, the pouch. An opened ready-to-use vial should be used right away.

1. Open the foil pouch by tearing on the rough edge along the seam of the pouch. Remove a ready-to-use vial of BROVANA.

- BROVANA.

 2. Carefully twist open the top of the ready-to-use vial and use it right away (Figure 1).

 [See figure 1 at top of previous page]
- 3. Squeeze all of the medicine from the ready-to-use vial into the nebulizer medicine cup/(reservoir) (Figure 2)
- 1 the the nebulizer mentance cup (regure 2). [See figure 2 at top (of previous page]
 4. Connect the nebulizer reservoir to the mouthpiece (Figure 3) or face mask (Figure 4). [See figure 4 at top of first column]. [See figure 4 at top of first column]
 5. Connect the nebulizer to the compressor (Figure 5).
- [See figure 5 at top of second column]
- 6. Sit in a comfortable; upright position. Flace the moun-piece in your mouth (Figure 6) (of put on the face mask) and turn on the compressor.

 [See figure 6 at top of second column].

 Breathe as calmly, deeply, and evenly as possible until no more mist is formed in the nebulizer reservoir. It takes

 Shakiff & 10 shiritis for adolf treatment.
- about 5 to 10 minutes for each treatment.

 8. Clean the nebulizer (see manufacturer's instructions). Rx Only
- This Medication Guide has been approved by the Food and Drug Administration VOSH gamen gast, an el dels sin SUNOVION vora sendificat e y los challed scalin Manufactured formande apolite? Agree is

Sunovion Pharmaceuticals Inc.
Marborough, MA 01752 USA
BROVANA is a registered trademark of Sunovion Pharmaceuticals Inc. ceuticals Inc. July 2011

Shown in Product Identification Guide, page 317

LATUDA

dand mireger a no flor studis-(lurasidone HCl) tablets for oral administration

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LATUDA safely and effectively. See full prescribing information for LATUDA.

LATUDA (LURASIDONE HCI) tablets for oral administra-

Initial U.S. Approval: 2010

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed

warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death, LATUDA is not approved for the treatment of patients with dementia-related psychosis

- INDICATIONS AND USAGE -

LATUDA is an atypical antipsychotic agent indicated for the treatment of patients with schizophrenia (1). Efficacy was established in four 6-week controlled studies of adult patients with schizophrenia (1). patients with schizophrenia (14.1).

- DOSAGE AND ADMINISTRATION

The recommended starting dose of LATUDA is 40 mg once daily. Initial dose titration is not required. The maximum recommended dose is 80 mg once daily. LATUDA should be taken with food (2.2) taken with food (2.2).

- DOSAGE FORMS AND STRENGTHS Tablets: 40 mg and 80 mg (3)

FREE CME AND LIABILITY REDUCTION SERVICES at PDR.net



-CONTRAINDICATIONS-

any known hypersensitivity to LATUDA or any components the formulation (4). n the formulation (4). Coadministration with a strong CYP3A4 inhibitor (e.g., ke-nconazole) and inducer (e.g., rifampin) (4).

WARNINGS AND PRECAUTIONS -

Cerebrovascular Adverse Reactions: An increased inci-dence of cerebrovascular adverse events (e.g., stroke, fran-sient ischemic attack) has been seen in elderly patients

with dementia related psychoses, treated with attypical and psychotic drugs, (5,2).

Neuroleptic Malignant Syndrome: Manage with immediate discontinuation and close monitoring (5,3).

Tardive Dyskinesia: Discontinue if clinically appropriate

Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and weight

changes include hypergry
gain (5.5).

Hyperglycemia and Diabetes Mellitus: Monitor patients for symptoms of hyperglycemia including polydipl
sia, polywria, polyphagia, and weakness. Monitor glucose
regularly in patients with diabetes or at risk for diabetes:

rved in patients treated with atypical antipsychotics. • Weight Gain. Gain in body weight has been observed, clinical monitoring of weight is recommended. Hyperprolactinemia: Prolactin elevations may occur

Leukopenia, Neutropenia, and Agranulocytosis have been Laukopenia, Neutropenia, and Agranulocytosis nave been reported with antipsychotics: Patients with a "pre-existing low white blood cell count (WBC) or a history of leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and LATUDA should be discontinued at the first-

Orthostatic Hypotension and Syncope: Dizziness, tachycardia or bradycardia, and syncope may occur, especially early in treatment. Use with caution in patients with

sign of a decline in WBC in the absence of other causative

known cardiovascular or cerebrovascular disease, and in antipsychotic-naive patients (6,8).

Selzures: Use cautiously in patients with a history of sel-zures or with conditions that lower the selzure threshold

Potential for Cognitive and Motor Impairment: Use cau-tion when operating machinery (5.10).

Suicide: The possibility of a suicide attempt is inherent in schizophrenia: Closely supervise high-risk patients

o.12),
See Full Prescribing Information for additional WARN-INGS and PRECAUTIONS.

-ADVERSE REACTIONS

Commonly observed adverse reactions (incidence ≥ 5% and at least twice the rate for placebo) included somnolence, akathisia, nausea, parkinsonism and agitation (6:2).

ion Pharmaceuticals Inc. at 877-737-7226 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch DRUG INTERACTIONS

·LATUDA is not recommended to be used in combination with strong CYP3A4 inhibitors, e.g., ketoconazole (4 and

Dose adjustment is recommended for moderate CYP3A4 inhibitors (e.g., diltiazem) (7.1).

LATUDA is not recommended to be used in combination with strong CYP3A4 inducers, e.g., rifampin (4 and 7-1)

—use in specific populations—

Geriatric Use: No dose adjustments required (8/5). Pregnancy: Use LATUDA during pregnancy only if the potential benefit justifies the potential risk (8.1).

Nursing Mothers: Breast feeding is not recommended Pediatric Use: Safety and effectiveness have not been es-

tablished (8:4). tablished (8,4).co gajis selegatasia adiju bet medilesi Renel Impairment: Dose adjustment is recommended

Hepatic Impairment: Dose adjustment is recommended ee 17 for PATIENT COUNSELING INFORMATION

n has shuban L agu straitean Revised 05/2011.

FULL PRESCRIBING INFORMATION: CONTENTS*
WARNINGS INOREASED MORTALITY IN ELDERLY
PATIENTS WITH DEMENTIA RELATED PSYCHOSIS
L. INDICATIONS AND USAGE

DOSAGE AND ADMINISTRATION

2:1:38 Schizophrenia 2 2:21 Administration Instructions 2:22 Administration Instructions

2.3. Dosage in Special Populations (1994) 1993 (DOSAGE FORMS AND STRENGTHS CONTRAINDICATIONS
WARNINGS AND PRECAUTIONS
5.1. Increased Mortality in Elderly Patients with Dementia-Related Psychosis (h) and the state of the sta ing Stroke Neuroleptic Malignant Syndrome 5.3. 5,4. 5,5. Tardive Dyskinesia Metabolic Changes Hyperprolactinemia hypergesis of affine Leukopenia, Neutropenia and Agranulocyto-5.7

Orthostatic Hypotension and Syncope Seizures Potential for Cognitive and Motor Impair-

5.11. Body Temperature Regulation and primaring

5.12. Suicide 5.13. Dysphagia OUTAJ 5.14. Us Use in Patients with Concomitant Illness ADVERSE REACTIONS va 5.14.

Overall Adverse Reaction Profile 62 Clinical Studies Experience Dose-Related Adverse Reactions 6.3.

Extrapyramidal Symptoms
Laboratory Test Abnormalities and ECG
Changes in Clinical Studies 6.5. Changes in Clinical Studies
Other Adverse Reactions Observed During
the Premarketing Evaluation of LATUDA
TRIPPA AUTIONS 6,6.

DRUG INTERACTIONS

7.1. Potential for Other Drugs to Affect LATUDA
7.2. Potential for LATUDA to Affect Other Drugs
USE IN SPECIFIC POPULATIONS

8.1. Pregnancy 8.2. Labor and Delivery 8.3. Nursing Mothers 8.4. Pediatric Use 8.5 Geriatric Use

Renal Impairment Renal Impairment Hepatic Impairment actional (তেন) সাহাজ Gender ACKSTA

8.9. Race
8.10. Smoking Status
DRUG ABUSE AND DEPENDENCE
9.1. Controlled Substance
0.5 Abuse

9.1. 9.2. 10. OVERDOSAGE

10 nd toyerDosage

14. as 10.1. do Human. Experience
14. as 10.2. no Management of Overdosage and and ignoral
14. and DESCRIPTION is all should be of ground the
12. as CLINICAL PHARMACOLOGY range give of edita.

ors stal 2.10, do Mechanism of Action assistas de god pour such of 12.20 and Pharmacodynamics as a decorated de del

Risertia 12/3 role Pharmacokinetics of unit at to little Holling 13/7 NONCLINICAL TOXICOLOGY

NONCLINICAL TOTICODGY
CLINICAL STUDIES

14.1 Schizophrenia

14.1 Schizophrenia

HOW SUPPLIED/STORAGE AND HANDLING
PATIENT COUNSELING INFORMATION

17.1 Increased Mortality in Elderly Patients

Increased Mortality in pure with Dementia-Related Psychosis in part with the part of the p WOT I

17.2 Neuroleptic Malignant Syndrome 17.3 Hyperglycemia and Diabetes Mellitus al 7.4 see Orthostatic Hypotension series of willing a 17.5 and Leukopenia/Neutropenia (17.5 and Leukopenia/Neutropenia)

17.6 Interference with Cognitive and Motor Per-

the symbol statement the relative section of the second section of the second section of the second section is a second section of the section of the second section of the second section of the second section of the section of the second section of the second section of the sec 17.8 Concomitant Medication and Alcohol
17.9 Heat Exposure and Dehydration

* Sections or subsections omitted from the full prescribing Information are not listed

FULL PRESCRIBING INFORMATION

WARNING: INCREASED MORTALITY IN EL-DERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Analyses of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, revealed a risk of death in drug-treated patients of between 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the rate of death in drug-treated patients was about 4.5% compared to a rate of about 2.6% in the placebo group. Although the causes of death were varied, most of the deaths appeared to be either cardiovas cular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia) in nature.

Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality. The extent to which the findings of increased mortality in observational studies may be attributed to the antipsychotic drug as opposed to some characteristic(s) of the patients is not clear.

LATUDA is not approved for the treatment of patients with dementia-related psychosis. [see Warnings and Precautions (5.1)].

INDICATIONS AND USAGE 1.

LATUDA is indicated for the treatment of patients with schizophrenia.

The efficacy of LATUDA in schizophrenia was established in four 6-week controlled studies of adult patients with schizophrenja [see Clinical Studies (14.1)].

The effectiveness of LATUDA for longer-term use, that is, for more than 6 weeks, has not been established in controlled studies. Therefore, the physician who elects to use LATUDA for extended periods should periodically revolute the long-term usefulness of the drug for the individual patient [see Dosage and Administration (2)].

DOSAGE AND ADMINISTRATION

2.1. Schizophrenia
The recommended starting dose of LATUDA is 40 mg once daily. Initial dose titration is not required. LATUDA has been shown to be effective in a dose range of 40 mg/day to

120 mg/day [see Clinical Studies (14.1)]. In the 6-week controlled trials, there was no suggestion of added benefit with the 120 mg/day dose, but there was a dose-related increase in certain adverse reactions. Therefore, the maximum recommended dose is 80 mg/day.

2.2. Administration Instructions
LATUDA should be taken with food (at least 350 calories)
[see Clinical Pharmacology (12)].

2.3. Dosage in Special Populations

Dosage adjustments are not recommended on the basis of age, gender, and race/see Use in Specific Populations (8)]. Dose adjustment is recommended in moderate and severe renal impairment patients. The dose in these patients should not exceed 40 mg/day [see Use in Specific Popula-

Dose adjustment is recommended in moderate and severe hepatic impairment patients The dose in these patients should not exceed 40 mg/day [see Use in Specific Popula-

Dosing recommendation for patients taking LATUDA con-comitantly with potential CYPSA4 inhibitors: When coad-ministration of LATUDA with a moderate CYPSA4 inhibitor such as dittiazem is considered; the dose should not exceed 40 mg/day, LATUDA should not be used in combination with a strong CYP3A4 inhibitor (e.g., ketoconazole) [see Contraindications (4), Drug Interactions (7.1)].

Dosing recommendation for patients taking LATUDA con-comitantly with potential CYP3A4 inducers: LATUDA should not be used in combination with a strong CYP3A4 inducer (e.g., rifampin) [see Contraindications (4), Drug Interactions (7.1)]

DOSAGE FORMS AND STRENGTHS

LATUDA tablets are available in the following shape and color (Table 1) with respective one-sided debossing 40 mg (white to off-white, round, 140°), or 80 mg (pale green, oval,

Table 1: CATUDA Tablet Presentations

Tablet Strei	ngth T	ablet Colo	Y/ Te	blet Marking:
<u>លៀត រណ៍ ស្ដេច៧</u>	W 66989*3DT	U0009.01.10		umilication It
40 mg	wh	ite to off-v	vhite	1.40
PIED zazda	mya Dan ba mya Dan ba	round	rm amarko Rizo kil ka	iselv toested
80 mg	ar diller m	le green o	val	L80
ห์ นบนโร คงได้	atv. beet st	MINISTER STREET	uillichaitas	clode central

An acontraindications and later against but a

4. CONTRAINDICATIONS

LATUDA is contraindicated in any patient with a known hypersensitivity to lurasidone HCl or any components in the formulation. Angioedema has been observed with lurasidone [see Adverse Reactions (6.6)].

LATUDA is contraindicated with strong CYP3A4 inhibitors (e.g., ketoconazole) and strong CYP3A4 inducers (e.g., rifampin) [see Drug Interactions (7.1)].

5. WARNINGS AND PRECAUTIONS

5.1. Increased Mortality in Elderly Patients with Dementia-Related Psychosis

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. LATUDA is not approved for the treatment of dementiarelated psychosis [see Boxed Warning].

RECEIVE FDA REQUIRED DRUG ALERTS INSTANTLY ONLINE, REGISTER at PDR.net



at, shotler to skydt	drissgpus adisus i Table 2: Change	n Fasting Glucose	ago in Special Popul.	800 8.000 000 000 000 000 000 000 000 00
is sufferious because	zeowni yest spani win LATUDA with Placebo with whi 20 mg/day	LATUDA 40 mg/day	LATUDA A 30 Mg/day	LATUDA 120 mg/day
Spatial and Scale des	் இத்த Mean Change froi	n Baseline (mg/dL)	dwyd bantabudhhila Tura nambr Adusa	84G 61 k s 2
	it sits id n=438 mqqe torrat a 0=71 A.t	ຸ້ n=352 -ໝວງວານ		n=283
Serum Glucose	-0.7 (1) (2) A STORE IN A STORE I	2.5	1.0.9 8 7 (L 9 35	* 2.5
	Proportion of Patients w	rith Shifts to ≥ 126 mg/	dL Greativelegge	vii ji ji ji
Serum Glucose (≥ 126 mg/dL)	8.6% (34/397) 11.7% (7/60)	14.3% (47/328)	10.0% (24/241)	10.0% (26/260)
"barelloris sea att	the discrept of LAC HAL to problem the	. Joseph and American Committee	soldher (A. on Ashana)	of Toron

- (1	317	Stration	books I.	blo 200	handa	in Fastina	Linide

Placebo 20'mg/day	LATUDA LATUDA 40 mg/day 80 mg/day 120 mg/day
atili valenti Mean Change from	
жылын жүүлгэ. ∪=418 , «жылыры эго ля∄1 , шыгы	n=341 graduate e n=263 vector accom n=268
Total cholesterol -8.5 -8.52.3	Οτζ 19.4 minbon 159.8 min pot 1 -3.8 m
Triglycerides -15.7 -29.1	nage (-6,2 /15,00/ 1 -15,00 14,2,00 14,2)
Proportion of Pati	ents with Shifts and and an ender on the control of
Total cholesterol 6.6% 13.8% (≥ 240 mg/dL) (23/350) (8/58)	7.3% 6.9% 3.8% (21/287) (15/216) (9/238)
Triglycerides (≥ 200 mg/dL) (39/312) 14.3%	14.0% 8.7% 10.5% (37/264) (17/196) (22/209)
The second section of	in the second of

Table 4: Mean Change in Weight (kg) from Baseline

Placebo 20 mg/day (n=450) (n=71)	LATUDA 40 mg/day (n=358)	LATUDA LATUDA 80 mg/day 120 mg/day (n≝279) (n=291)
All Patients 50:26 10 1351 0.15	0.67	0.68

Cerebrovascular Adverse Reactions, Including Stroke

In placebo-controlled trials with risperidone, aripiprazole, and olanzapine in elderly subjects with dementia, there was a higher incidence of cerebrovascular adverse reactions (cerebrovascular accidents and transient ischemic attacks), including fatalities, compared to placebo-treated subjects, LATUDA is not approved for the treatment of patients with dementia-related psychosis [see also Boxed Warning and Warnings and Precautions (5.1)].

Neuroleptic Malignant Syndrome

A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with administration of antipsychotic drugs, including LATUDA.

Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatinine phosphokinase, myoglobinuria

(rhabdomyolysis), and acute renal failure. The diagnostic evaluation of patients with this syndrome is complicated. It is important to exclude cases where the clinical presentation includes both serious medical illness (e.g. pneumonia, systemic infection) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fe

ver, and primary central nervous system pathology.

The management of NMS should include: 1), immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy; 2) intensive symptomatic treatment and medical monitoring; and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for

If a patient requires antipsychotic drug treatment after reovery from NMS, the potential reintroduction of drug therapy should be carefully considered. If reintroduced, the patient should be carefully monitored, since recurrences of NMS have been reported standard of the standard of

5.4. Tardive Dyskinesia is a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements that can

develop in patients treated with antipsychotic drugs. develop in patients treated with antipsychotic drugs. Ai-though the prevalence of the syndrome appears to be high-est among the elderly, especially elderly women, it is impos-sible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia

The risk of developing tardive dyskinesia and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses

There is no known treatment for established cases of tardive dyskinesia, 'although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic-treatment, itself, however, may suppress/(or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown. Given these considerations, LATUDA should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic, antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that (1) is known to respond to antipsychotic drugs, and (2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the There is no known treatment for established cases of tar-

propriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought.

The need for continued treatment should be reassessed pe-

riodically.

If signs and symptoms of tardive dyskinesia appear in a pa tient on LATUDA, drug discontinuation should be considered. However, some patients may require treatment with LATUDA despite the presence of the syndrome.

5.5. Metabolic Changes Atypical, antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cere-brovascular risk. These metabolic changes include hyperglycemia, dyshpidemia, and body weight gain, While all of the drugs in the class have been shown to produce some metabolic changes, each drug has its own specific risk proeroten mi isinomu enu co e

REP

for pla tients LATU male tin el treate In the label

media (n=18 week Jissu one-th in vitr of the tected increa

neopla condu Neith to dat strati mans, sive. 5.7. Leuko ment fatal c Роввів

pre-ex drug-i

existir neutr

monit and L

cline i Patien fever promp vere 1

should until 1

5.8, LATU

to its ortho

term. placeb 0.2% (

of ortl (≥ 20

≥ 10 b

pine to thosta

with L

with I

LATU

know

myoca

ties), c the pa

and tr

toring

tients

cautio dition

deme

be mo

In she

sions

LATU

tients

5.10. LATU

Dair i

In sho porte LATU

specti

80mn

80mn

tion a

Patie

mach

ably them

5.11.

Dism

ature ate ce

who v

5.9

Hyperglycemia and Diabetes Mellitus

Hyperglycemia, in some cases, extreme and associated with
ketoacidosis or hyperosmolar coma or death, has been reported in patients treated with atypical antipsychotics. As
sessment of the relationship between atypical antipsychotics
use and glucose abnormalities is complicated by the
bility of an increased background risk of diabetes mellitus
the relationship increasing incidents. use and glucose abnormalities is complicated by in the posibility of an increased background risk of diabetes mellitus
in patients with schizophrenia and the increasing incluse
of diabetes mellitus in the general population. Given these
confounders, the relationship between atypical antipsy
chotic use and hyperglycemia-related adverse events is no
completely understood. However, epidemiological studes
suggest an increased risk of treatment emergen
hyperglycemia-related adverse events in patients treate
with the atypical antipsychotics. Because LATUDA was not
marketed at the time these studies were performed, it is no
known if LATUDA is associated with this increased risk.
Patients with an established diagnosis of diabetes mellitus
who are started on atypical antipsychotics should be monitored regularly for worsening of glucose control. Patients
with risk factors fon diabetes mellitus (e.g., obesity familhistory of diabetes) who are starting treatment with avyncal antipsychotics should undergo fasting blood glucose testing at the beginning of treatment and periodically during
treatment. Any patient treated with atypical antipsychotic
should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polynnaja, and weakness, Patients who develop symptoms of hyperglycemia including blood glucose testing. In some cases, hyperglycemia during
treatment with atypical antipsychotics should undergo fasting blood glucose testing. In some cases, hyperglycemia has
resolved when the atypical antipsychotics was discontinues. ing blood glucose testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic was discontinued. however, some patients required continuation of anti-diabetic treatment despite discontinuation of the suspect

drug.
Pooled data from short-term, placebo-controlled studies are

routed that in Table 2, 2 and a tipoparal because (188) [See table 2 above] In the uncontrolled, longer-term studies (primarily open label extension studies). LATUDA was associated, with a mean change in glucose of +1.6 mg/dL at week 24 (n=186) +0.3 mg/dL at week 36 (n=246) and +1.2 mg/dL at week 52 (n=248). ver440 fed as no thes ruley set Dyslipidemia in whenever they set

Dyslipidemia in the laterations in lipids have been observed in particular in the lateration in lipids have been observed in particular in the lateration in lipids have been observed in particular in the lateration in lipids have been observed in particular in the lateration in lipids have been observed in particular in the lateration in lipids have been observed in particular in the lateration in lipids have been observed in particular in the lateration in lipids have been observed in particular in the lateration in lipids have been observed in particular in the lateration in lipids have been observed in particular in the lateration in lipids have been observed in particular in the lateration in lipids have been observed in particular in the lateration in lipids have been observed in particular in the lateration in lipids have been observed in particular in the lateration in lipids have been observed in particular in the lateration in lipids have been observed in particular in the lateration in lipids have been observed in particular in the lateration in lipids have been observed in particular in the lateration in lipids have been observed in lipids have been observed in lateration i tients treated with atypical antipsychotics. Pooled data from short-term, placebo-controlled studies are presented in Table 3.

Isole 3. [See table 3 above] [In the uncontrolled, longer-term studies (primarily openlabel extension studies), LATUDA was associated with a mean change in total cholesterol and triglycerides of 4.2 (n=186) and -13.6 (n=187) mg/dL at week 24, -1.9 (n=238) and -3.5 (n=238) mg/dL at week 36 and +3.6 (n=243) and -6.5 (n=243) mg/dL at week 52, respectively

Weight Gain

Weight gain has been observed with atypical antipsychotic presented in Table 4. The mean weight gain was 0.75 kg for LATUDA-treated patients compared to 0.26 kg for placebo treated patients. In Study 3-lisec Clinical Studies (14.1) change in weight from baseline for clanzapine was 4.15ks. The proportion of patients with a ≥ 7% increase in body weight (at Endpoint) was 5.6% for LATUDA-treated patients versus 4.0% for placebo-treated patients.

[See table 4 above] A special distribution of the uncontrolled, longer-term studies (primarily open-label extension studies). LATUDA was associated with a mean change in weight of -0.38 kg at week 24 (n=581). 0.47 kg at week 36 (n=303) and 0.71 kg at week 52 (n=244)

Hyperprolactinemia

As with other drugs that antagonize dopamine D2 receptors,

LATUDA elevates prolactin levels.

Hyperprolactinemia may suppress hypothalamic GnRH, resulting in reduced pituitary gonadotrophin secretion. This in turn, may inhibit reproductive function by impairing go nadal steroidogenesis in both female and male patients. Ga-lactorrhea, amenorrhea, gynecomastia, and impotence have been reported with prolactin-elevating compounds. Long standing hyperprolactinemia when associated with hypogo-nadism may lead to decreased bone density in both female

and male patients [see Adverse Reactions (6)].

In short-term, placebo-controlled studies, the median change from baseline to endpoint in prolactin levels for LATUDA-treated patients was 1.1 ng/mL and was -0.6 ng/mL in the placebo-treated patients. The increase in prolactin was greater in female patients; the median change from baseline to endpoint for females was 1.5 ng/mh and was 1.1 ng/mL in males, The increase in prolactin concentrations was dose-dependent (Table 5).

[See table 5 at top of next page] (In the proportion of patients with prolactin elevations ≥ 5% ULN was 3.6% for LATUDA-treated patients versus 0.7%

180 90 40 FREE CME AND LIABILITY REDUCTION SERVICES at PDR net 12 444 1923



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

